Education
About Us
Working with TipRanks
Follow Us
Terns Pharmaceuticals (TERN)
NASDAQ:TERN
TERN Analyst Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TERN Stock 12 Month Forecast
Average Price Target
$27.80
▲(7.79% Upside)
| Highest Price Target$36.00 | Average Price Target$27.80 | Lowest Price Target$15.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Mizuho Securities
$33
Buy
27.96%
Upside
Reiterated
11/26/25
Citizens JMP
$25→$35
Buy
35.71%
Upside
Reiterated
11/26/25
Barclays
$28→$36
Buy
39.59%
Upside
Reiterated
11/24/25
William Blair
―
Buy
―
Reiterated
11/20/25
Promising Outlook for TERN-701 in CML Market: Buy Rating Affirmed by AnalystBillion as at ASH Novartis (NVS $127.31) hosted its annual Meet the Management event and raised peak sales guidance for Scemblix to $4 billion-plus, from $3 billion-plus previously, which we believe has positive read-through to Terns’s allosteric BCR::ABL1 inhibitor, TERN-701, in chronic myeloid leukemia (CML). Specifically, Scemblix garnered 56% market share in the second-line setting and 23% in the treatment-naive segment. Driven by the robust uptake across multiple lines, the franchise is annualizing about $1.4 billion based on third-quarter worldwide sales while growing at a 95% constant-currency rate.
Truist Financial
$28→$35
Buy
35.71%
Upside
Reiterated
11/19/25
BMO Capital
$35
Buy
35.71%
Upside
Reiterated
11/17/25
TD Cowen
―
Buy
―
Reiterated
11/13/25
H.C. Wainwright
$20
Buy
-22.45%
Downside
Reiterated
11/11/25
Wall Street Analysts Are Bullish on Top Healthcare PicksValuation and Risks. Our Buy rating and $20 PT is based on a risk-adjusted per share value as the sum of $16.93/ per share as a placeholder value for TERN-701 for CML and $3.18 per share representing excess cash beyond two years of runway. In our valuation model, we employ an 11.0% discount rate, which we believe adequately reflects the overall risks of Terns' development pipeline.
Jefferies
$28→$35
Buy
35.71%
Upside
Reiterated
11/03/25
Oppenheimer
$20→$17
Buy
-34.08%
Downside
Reiterated
10/22/25
UBS
$17
Buy
-34.08%
Downside
Reiterated
09/15/25
Anticipated Data Updates and Underappreciated Catalysts Drive Buy Rating for Terns PharmaceuticalsColor from TERN mgmt at our fireside chat - we think obesity and CML data updates in early 4Q/4Q respectively are underappreciated catalysts We hosted a fireside chat with TERN mgmt (Amy Burroughs, CEO, Emil Kuriakose, CMO, and Andrew Gengos, CFO) ahead of two major readouts for TERN later this year - Ph2 topdata for TERN-601 (oral GLP-1) in obesity in early 4Q, and a data update from the Ph1 trial of TERN-701 (allosteric BCR-ABL) in chronic myeloid leukemia (CML) in 4Q. We think CML is a key focus for the stock as the company's main focus going forward (looking to partner in obesity).
J.P. Morgan
$14
Hold
-45.72%
Downside
Reiterated
05/09/25
Westpark Capital
$7.5
Hold
-70.92%
Downside
Reiterated
12/04/24
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Mizuho Securities
$33
Buy
27.96%
Upside
Reiterated
11/26/25
Citizens JMP
$25→$35
Buy
35.71%
Upside
Reiterated
11/26/25
Barclays
$28→$36
Buy
39.59%
Upside
Reiterated
11/24/25
William Blair
―
Buy
―
Reiterated
11/20/25
Promising Outlook for TERN-701 in CML Market: Buy Rating Affirmed by AnalystBillion as at ASH Novartis (NVS $127.31) hosted its annual Meet the Management event and raised peak sales guidance for Scemblix to $4 billion-plus, from $3 billion-plus previously, which we believe has positive read-through to Terns’s allosteric BCR::ABL1 inhibitor, TERN-701, in chronic myeloid leukemia (CML). Specifically, Scemblix garnered 56% market share in the second-line setting and 23% in the treatment-naive segment. Driven by the robust uptake across multiple lines, the franchise is annualizing about $1.4 billion based on third-quarter worldwide sales while growing at a 95% constant-currency rate.
Truist Financial
$28→$35
Buy
35.71%
Upside
Reiterated
11/19/25
BMO Capital
$35
Buy
35.71%
Upside
Reiterated
11/17/25
TD Cowen
―
Buy
―
Reiterated
11/13/25
H.C. Wainwright
$20
Buy
-22.45%
Downside
Reiterated
11/11/25
Wall Street Analysts Are Bullish on Top Healthcare PicksValuation and Risks. Our Buy rating and $20 PT is based on a risk-adjusted per share value as the sum of $16.93/ per share as a placeholder value for TERN-701 for CML and $3.18 per share representing excess cash beyond two years of runway. In our valuation model, we employ an 11.0% discount rate, which we believe adequately reflects the overall risks of Terns' development pipeline.
Jefferies
$28→$35
Buy
35.71%
Upside
Reiterated
11/03/25
Oppenheimer
$20→$17
Buy
-34.08%
Downside
Reiterated
10/22/25
UBS
$17
Buy
-34.08%
Downside
Reiterated
09/15/25
Anticipated Data Updates and Underappreciated Catalysts Drive Buy Rating for Terns PharmaceuticalsColor from TERN mgmt at our fireside chat - we think obesity and CML data updates in early 4Q/4Q respectively are underappreciated catalysts We hosted a fireside chat with TERN mgmt (Amy Burroughs, CEO, Emil Kuriakose, CMO, and Andrew Gengos, CFO) ahead of two major readouts for TERN later this year - Ph2 topdata for TERN-601 (oral GLP-1) in obesity in early 4Q, and a data update from the Ph1 trial of TERN-701 (allosteric BCR-ABL) in chronic myeloid leukemia (CML) in 4Q. We think CML is a key focus for the stock as the company's main focus going forward (looking to partner in obesity).
J.P. Morgan
$14
Hold
-45.72%
Downside
Reiterated
05/09/25
Westpark Capital
$7.5
Hold
-70.92%
Downside
Reiterated
12/04/24
Best Analysts Covering Terns Pharmaceuticals
1 Month
xxx
Success Rate
8/12 ratings generated profit
Average Return
+32.40%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +32.40% per trade.
3 Months
xxx
Success Rate
8/12 ratings generated profit
Average Return
+54.87%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +54.87% per trade.
1 Year
Success Rate
7/12 ratings generated profit
Average Return
+45.82%
reiterated a buy rating 10 days ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +45.82% per trade.
2 Years
xxx
Success Rate
12/14 ratings generated profit
Average Return
+280.94%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +280.94% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TERN Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
5
5
10
14
18
Buy
0
1
1
4
16
Hold
2
1
4
6
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
7
15
24
39
Each month's total comprises the sum of three months' worth of ratings.
TERN Financial Forecast
TERN Stock Forecast FAQ
What is TERN’s average 12-month price target, according to analysts?
Based on analyst ratings, Terns Pharmaceuticals’s 12-month average price target is 27.80.
What is TERN’s upside potential, based on the analysts’ average price target?
Terns Pharmaceuticals has 7.79% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TERN a Buy, Sell or Hold?
Terns Pharmaceuticals has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
What is Terns Pharmaceuticals’s price target?
The average price target for Terns Pharmaceuticals is 27.80. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $36.00 ,the lowest forecast is $15.00. The average price target represents 7.79% Increase from the current price of $25.79.
The highest analyst price target is $36.00 ,the lowest forecast is $15.00. The average price target represents 7.79% Increase from the current price of $25.79.
What do analysts say about Terns Pharmaceuticals?
Terns Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of TERN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.